Standard BioTools Inc. reported preliminary fourth‑quarter and full‑year 2025 financial results that surpassed the company’s own guidance. The company’s combined revenue for Q4 2025 rose to $56 million, with continuing‑operations revenue of $24 million, while full‑year 2025 combined revenue reached $185 million and continuing‑operations revenue totaled $85 million. These figures represent a 20% year‑over‑year increase in Q4 revenue compared with $46.5 million in Q4 2024, and a 5.5% year‑over‑year rise in full‑year revenue versus $175.1 million in the prior year. The full‑year numbers include revenue from the SomaLogic business, which explains why continuing‑operations revenue is lower than the prior year’s total.
The company’s segment mix continued to shift. Consumables revenue declined 17% year‑over‑year, while instrument revenue fell 3% year‑over‑year in the most recent quarter. Despite these headwinds, overall revenue growth was driven by stronger demand in core instrument and service segments and by modest pricing gains that offset the decline in consumables sales.
Gross‑margin performance improved in the first half of 2025, with a reported gross margin of 48.8% and a non‑GAAP gross margin of 54.1% in Q2 2025. Management highlighted disciplined cost control and operational efficiencies as key drivers of margin expansion, noting that these measures have helped offset the impact of lower consumables sales.
The company’s liquidity position is a central pillar of its strategic outlook. Upon completion of the SomaLogic divestiture to Illumina, Standard BioTools expects to hold approximately $550 million in cash, a figure that will provide a substantial buffer and enable the company to pursue a path to adjusted EBITDA breakeven in 2026. The divestiture is expected to close in the first half of 2026, further strengthening the company’s balance sheet.
CEO Michael Egholm emphasized that the company is moving steadily toward profitability. He said the organization is “streamlining operations and sharpening its operating model” and that the sale of SomaLogic will create “real strategic flexibility.” Egholm added that the company’s focus on cost discipline and operational rigor has positioned it to pursue disciplined M&A and build a diversified leader in life sciences.
Investors responded positively to the results, with analysts noting that the company’s revenue beat internal guidance and that the strong cash outlook provides a solid foundation for future growth. The market reaction reflects confidence in Standard BioTools’ ability to execute on its strategic priorities and to achieve profitability in the near term.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.